Italia markets closed

GSK plc (GSK.L)

LSE - LSE Prezzo differito. Valuta in GBp (0.01 GBP).
Aggiungi a watchlist
1.708,60+3,40 (+0,20%)
Alla chiusura: 05:14PM GMT
Schermo intero
Chiusura precedente1.705,20
Aperto1.701,60
Denaro1.301,00 x 0
Lettera1.764,00 x 0
Min-Max giorno1.699,21 - 1.713,00
Intervallo di 52 settimane1.302,60 - 1.725,81
Volume8.297.306
Media Volume9.139.472
Capitalizzazione69,814B
Beta (5 anni mensile)0,26
Rapporto PE (ttm)14,24
EPS (ttm)1,20
Prossima data utili01 mag 2024
Rendimento e dividendo (futuro)0,64 (3,75%)
Data ex dividendo22 feb 2024
Stima target 1AN/D
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

    STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my

  • GlobeNewswire

    SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

    SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte